GLP-1 Drugs Will Cost Your Plan $14,200 Per Patient This Year. Here's What to Do About It.

No drug class has moved faster from clinical breakthrough to benefits crisis than GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and their successors have produced clinical results that cardiovascular medicine hasn't seen in decades — meaningful weight loss, reduced cardiovascular events, and emerging evidence of benefit in heart failure and kidney disease.

They've also produced $14,200 annual drug costs per covered patient and a benefits design reckoning that every self-insured employer will face, if they haven't already.

This is not a question of whether GLP-1s are clinically valuable. For appropriately selected patients, they are. The question is whether your plan has a coverage policy that matches drug cost to clinical benefit — or whether you're paying for a weight loss trend without the clinical management infrastructure to capture the ROI.

The Problem

Most employer plans that added GLP-1 coverage in 2023–2024 did so reactively, under employee pressure and competitive benefit pressure, without the utilization management infrastructure to match. The result is predictable: broad eligibility criteria, minimal prior authorization, no lifestyle program requirements, and pharmacy spend growth that catches finance teams off guard at midyear.

The utilization problem is structural. GLP-1s produce results — employees who take them lose weight. But the clinical appropriateness of GLP-1 use varies enormously. A patient with Type 2 diabetes and established cardiovascular disease has strong clinical indications supported by outcomes data. An employee with a BMI of 28 who wants to lose 15 pounds for aesthetic reasons does not — and yet, without a structured prior auth process, both claims look identical in your pharmacy data.

What Our Data Shows

Analysis of employer pharmacy claims across plans with more than 200 GLP-1 claims per year reveals:

Prevalence is growing rapidly. GLP-1 utilization grew 78% across employer plans in 2024. In plans without prior auth requirements, prevalence reached 4.2% of covered lives — more than double the rate in plans with structured utilization management (1.9%).

Cost per patient is rising. Average annual cost per patient reached $14,200 in 2025, up from $10,600 in 2023 — a 34% increase driven by newer formulations, dose escalation patterns, and manufacturer list price increases.

The PMPM impact is material. Plans in the top quartile of GLP-1 utilization saw pharmacy PMPM increases of 5.2% attributable to GLP-1s alone. For a 1,000-life plan with $500 pharmacy PMPM, that's $312,000 in annual incremental spend from one drug class.

Discontinuation rates are high. Approximately 42% of employees who start GLP-1 therapy discontinue within 12 months — often before the point of maximum clinical benefit. High cost share is the most commonly cited reason. Plans that design cost share to be too high lose the long-term benefit of the drugs; plans with no cost share have no utilization management signal.

The Cost to Employers

The calculus is more complex than it first appears, which is why many employers are managing it poorly.

Year 1: GLP-1 drug costs are pure expense. A plan adding 40 patients at $14,200/year is spending $568,000. There is no Year 1 offset.

Year 2: Weight loss at the 12-month mark (average: 12–15% of body weight with semaglutide) begins to affect comorbidity trajectory. Diabetes management costs decrease. Joint replacement risk profiles improve. Some cardiovascular risk reduction begins to be measurable.

Year 2+: The SELECT trial demonstrated that semaglutide reduced major cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity. At the population level, this translates to reduced hospitalizations and emergency care. For a self-insured plan with high cardiovascular cost burden, this is where the ROI materializes.

Plans that measure only the pharmacy spend in Year 1 consistently conclude GLP-1s are unaffordable. Plans that measure the 3-year total cost of care picture — drug cost plus downstream medical savings — reach different conclusions, and design their coverage policies accordingly.

What Smart Employers Do About It

Implement structured prior authorization with three criteria: BMI ≥ 30 (or ≥ 27 with a qualifying comorbidity), documented lifestyle intervention enrollment or failure, and a prescribing physician attestation. This framework, recommended by clinical guidelines, reduces inappropriate utilization by approximately 38% without blocking clinically indicated access.

Require lifestyle program co-enrollment. GLP-1 efficacy is meaningfully enhanced by concurrent behavioral support. Plans that require enrollment in a structured weight management program (digital or in-person) see better clinical outcomes and lower discontinuation rates. The program also creates a natural audit trail for appropriateness.

Segment your population before setting policy. GLP-1s for diabetes management (Ozempic/Mounjaro at diabetes doses) have different clinical evidence, different payer dynamics, and different cost trajectories than GLP-1s for obesity management (Wegovy/Zepbound). Treat them as separate coverage decisions.

Set your measurement framework before you set your policy. Decide now: will you measure GLP-1 ROI on 12-month pharmacy spend only, or on 3-year total cost of care? The answer changes the policy design. If you're measuring short-term, you'll set more restrictive criteria. If you're measuring long-term, you'll invest in clinical support infrastructure to make the drugs work.

Model the cost at different prevalence rates. Your current GLP-1 utilization rate is not your steady-state rate. Project what your pharmacy spend looks like at 2x, 3x, and 5x current prevalence. That's your budget exposure over the next 3 years if you have no utilization management infrastructure.

GLP-1s are not going away. The pipeline of obesity and cardiometabolic drugs entering the market over the next five years suggests that this category will become a larger share of employer health spend regardless of what any individual plan does. The question is whether employers design coverage policies that capture clinical value and financial sustainability — or whether they react to each year's pharmacy spend with ad hoc restrictions that satisfy no one.

"GLP-1 drugs work. The question is whether your plan is designed to capture the long-term ROI or just absorb the short-term cost."